Article Text

Download PDFPDF
CASE REPORT
Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition
  1. Anthony A Donato1 and
  2. Ronald Krol2
  1. 1 Internal Medicine, Reading Health System, West Reading, Pennsylvania, USA
  2. 2 Pulmonary and Critical Care, Tower Health System, West Reading, Pennsylvania, USA
  1. Correspondence to Dr Anthony A Donato, anthony.donato{at}towerhealth.org

Abstract

Programmed cell death-1 (PD-1) inhibitors stimulate immune recognition of tumour cells in cancer patients, but have significant autoimmune side effects including pneumonitis. We report the case of a patient with asthma and mild eosinophilia who developed unusual pulmonary side effect of bronchiectasis, severe eosinophilia (absolute eosinophil count: 3200 c/mm3) and elevated IgE levels (7050 IU/mL; normal: <164 IU/mL) 4 months into therapy with the PD-1 inhibitor pembrolizumab. Aspergillus fumigatus IgG was elevated at 15.60 U/mL (normal: <12.01 U/mL). He responded to therapy with corticosteroids and voriconazole and was able to resume pembrolizumab thereafter with good clinical response.

  • lung cancer (oncology)
  • unwanted effects / adverse reactions
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors AAD and RK both had access to all of the data, contributed significantly to the manuscript and the final editing of the paper.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.